



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,  
Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 22<sup>nd</sup> November, 2022

To,

The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Sub: Disclosure of Related Party Transactions for the half year ended 30<sup>th</sup> September, 2022**

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details on Related Party Transactions for the half year ended 30<sup>th</sup> September, 2022, prepared in accordance with the format specified by SEBI vide circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22<sup>nd</sup> November, 2021.

This is for your information and records.

Thanking you,

Yours faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma  
Company Secretary**

Encl: a/a

**SMS PHARMACEUTICALS LIMITED**

**Disclosure of Related Party Transactions for the half year ended 30th September, 2022**

**(Rs. in Lakhs)**

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
Sr no	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	SMS Pharmaceuticals Limited	VKT Pharma Private Limited		Associate Company	Sale of goods	14,750.00	449.92	385.63	512.52								
					Purchase of goods	200.00	-	385.63	512.52								
					Rent Received	50.00	12.78	385.63	512.52								
2			SMS Lifesciences India Limited		Promoters holding more than 10 % of total equity	Purchase of goods	2,000.00	293.40	-46.02	-48.87							
3		Raghavendra Engineering Industries (India) Private Limited		Relative of Promoter	Purchase of goods	1,500.00	47.34	-38.53	3.65								
					Sale of goods	150.00	22.23	-38.53	3.65								
4			Eshwar Coal Movers		Relative of Promoter	Purchase of goods	500.00	94.51	-9.19	-79.67							
5			Ramesh Babu Potluri		Key Management Personnel	Remuneration Paid		156.07	80.86	12.30							
6		Vamsi Krishna potluri		Key Management Personnel	Remuneration Paid		33.00	190.71	3.02								
7		Lakshmi Narayana Tammineedi		Key Management Personnel	Remuneration Paid		11.66	1.31	1.57								
8		Thirumalesh T		Key Management Personnel	Remuneration Paid		7.40	1.13	1.06								
<b>Notes:</b> 1.The value of the related party transactions with VKT Pharma Private Limited, the amount approved by the Audit Committee/ Board of Directors/ Shareholders of SMS Pharmaceuticals Limited for the period from the conclusion of the 34th AGM held in the year 2022 to till the conclusion of the 35th AGM to be held in the year 2023. 2. The PAN details are not to be included in the disclosure pursuant to guidance note issued by the Stock Exchanges. 3.Dividend paid by SMS Pharmaceuticals Limited to related parties is not included in statement above since payment of dividend by a listed company is not a related party transaction as per Regulation 2(1)(zc) of the SEBI LODR Regulations. 4. The above statement does not include the Sitting Fee paid to the Directors of SMS Pharmaceuticals Limited																	